BACKGROUND & AIMS: Gastric cancer evolves in the setting of a pathologic mucosal milieu characterized by both loss of acid-secreting parietal cells and mucous cell metaplasias. Indeed, mucous cell metaplasia is considered the critical preneoplastic lesion for gastric cancer. Previous investigations have shown that infection of mice with Helicobacter felis or induction of acute parietal cell loss with the drug DMP-777 leads to the emergence of a type of metaplasia designated spasmolytic polypeptide-expressing metaplasia (SPEM). We have hypothesized that SPEM arises from proliferating cells in gland bases, either from a cryptic progenitor cell or by transdifferentiation of mature chief cells. METHODS: Taking advantage of the chief cell-restricted expression of Mist1-Cre-ER(T2), we used lineage mapping to examine whether SPEM lineages were derived from chief cells in 3 independent models of induction by DMP-777 treatment, L-635 treatment, or H felis infection. RESULTS: Treatment of mice with L-635 for 3 days led to rapid parietal cell loss, induction of a prominent inflammatory infiltrate, and emergence of SPEM. In all 3 models, SPEM developed, at least in part, from transdifferentiation of chief cells. We further found that acute parietal cell loss in the setting of inflammation (L-635 treatment) led to more rapid induction and expansion of SPEM derived from transdifferentiation of chief cells. CONCLUSIONS: These studies provide direct evidence by lineage tracing that SPEM evolves from differentiated chief cells. Thus, mature gastric chief cells have the ability to act as cryptic progenitors and reacquire proliferative capacity within the context of mucosal injury and inflammation.
BACKGROUND & AIMS:Gastric cancer evolves in the setting of a pathologic mucosal milieu characterized by both loss of acid-secreting parietal cells and mucous cell metaplasias. Indeed, mucous cell metaplasia is considered the critical preneoplastic lesion for gastric cancer. Previous investigations have shown that infection of mice with Helicobacter felis or induction of acute parietal cell loss with the drug DMP-777 leads to the emergence of a type of metaplasia designated spasmolytic polypeptide-expressing metaplasia (SPEM). We have hypothesized that SPEM arises from proliferating cells in gland bases, either from a cryptic progenitor cell or by transdifferentiation of mature chief cells. METHODS: Taking advantage of the chief cell-restricted expression of Mist1-Cre-ER(T2), we used lineage mapping to examine whether SPEM lineages were derived from chief cells in 3 independent models of induction by DMP-777 treatment, L-635 treatment, or H felis infection. RESULTS: Treatment of mice with L-635 for 3 days led to rapid parietal cell loss, induction of a prominent inflammatory infiltrate, and emergence of SPEM. In all 3 models, SPEM developed, at least in part, from transdifferentiation of chief cells. We further found that acute parietal cell loss in the setting of inflammation (L-635 treatment) led to more rapid induction and expansion of SPEM derived from transdifferentiation of chief cells. CONCLUSIONS: These studies provide direct evidence by lineage tracing that SPEM evolves from differentiated chief cells. Thus, mature gastric chief cells have the ability to act as cryptic progenitors and reacquire proliferative capacity within the context of mucosal injury and inflammation.
Authors: Victoria G Ramsey; Jason M Doherty; Christopher C Chen; Thaddeus S Stappenbeck; Stephen F Konieczny; Jason C Mills Journal: Development Date: 2007-01 Impact factor: 6.868
Authors: Jeanmarie Houghton; Calin Stoicov; Sachiyo Nomura; Arlin B Rogers; Jane Carlson; Hanchen Li; Xun Cai; James G Fox; James R Goldenring; Timothy C Wang Journal: Science Date: 2004-11-26 Impact factor: 47.728
Authors: Anna L Means; Ingrid M Meszoely; Kazufumi Suzuki; Yoshiharu Miyamoto; Anil K Rustgi; Robert J Coffey; Christopher V E Wright; Doris A Stoffers; Steven D Leach Journal: Development Date: 2005-07-14 Impact factor: 6.868
Authors: Koji Nozaki; Masako Ogawa; Janice A Williams; Bonnie J Lafleur; Vivian Ng; Ronny I Drapkin; Jason C Mills; Stephen F Konieczny; Sachiyo Nomura; James R Goldenring Journal: Gastroenterology Date: 2007-12-04 Impact factor: 22.682
Authors: Nils Habbe; Guanglu Shi; Robert A Meguid; Volker Fendrich; Farzad Esni; Huiping Chen; Georg Feldmann; Doris A Stoffers; Stephen F Konieczny; Steven D Leach; Anirban Maitra Journal: Proc Natl Acad Sci U S A Date: 2008-11-21 Impact factor: 11.205
Authors: Nick Barker; Johan H van Es; Jeroen Kuipers; Pekka Kujala; Maaike van den Born; Miranda Cozijnsen; Andrea Haegebarth; Jeroen Korving; Harry Begthel; Peter J Peters; Hans Clevers Journal: Nature Date: 2007-10-14 Impact factor: 49.962
Authors: Massimo Rugge; Matteo Fassan; Marco Pizzi; Fabio Farinati; Giacomo Carlo Sturniolo; Mario Plebani; David Y Graham Journal: World J Gastroenterol Date: 2011-11-07 Impact factor: 5.742
Authors: Victoria G Weis; Josane F Sousa; Bonnie J LaFleur; Ki Taek Nam; Jared A Weis; Paul E Finke; Nadia A Ameen; James G Fox; James R Goldenring Journal: Gut Date: 2012-07-07 Impact factor: 23.059
Authors: Sangho Jeong; Eunyoung Choi; Christine P Petersen; Joseph T Roland; Alessandro Federico; Rossana Ippolito; Francesco P D'Armiento; Gerardo Nardone; Osamu Nagano; Hideyuki Saya; Marco Romano; James R Goldenring Journal: United European Gastroenterol J Date: 2016-06-23 Impact factor: 4.623
Authors: Joseph T Roland; David M Bryant; Anirban Datta; Aymelt Itzen; Keith E Mostov; James R Goldenring Journal: Proc Natl Acad Sci U S A Date: 2011-01-31 Impact factor: 11.205
Authors: Shradha S Khurana; Terrence E Riehl; Benjamin D Moore; Matteo Fassan; Massimo Rugge; Judith Romero-Gallo; Jennifer Noto; Richard M Peek; William F Stenson; Jason C Mills Journal: J Biol Chem Date: 2013-04-15 Impact factor: 5.157